Brazil deal for Tissue Regenix

MEDICAL device firm Tissue Regenix has struck a deal that will help it move into a global market worth more than £600m.

The deal has been struck with the Pontifical Catholic University of Parana and Cardioprotese, both in Brazil and considered world leaders in the heart valve field.

The deal gives Tissue Regenix access to data that will help it commercialise a heart valve product that uses its dCELL technology that is designed to prevent rejection by the body.

It will also hand the York-based firm exclusive worldwide commercialisation rights, except in Brazil, over products developed as part of the partnership including a new version of an existing heart valve which has already been used in 1,200 patients.

Tissue Regenix will work with the University to further develop its dCELL technology which it already uses to manufacture a patch made from pig tissue that can be used to repair blood vessels.

Antony Odell, managing director of Tissue Regenix, said: “The global heart valve market represents a major opportunity for Tissue Regenix, we look forward to commercializing the dCELL heart valve and making this product available worldwide to surgeons and patients.”